CVRx, Inc. (CVRX)
| Market Cap | 133.48M -24.7% |
| Revenue (ttm) | 59.07M +11.7% |
| Net Income | -52.66M |
| EPS | -2.01 |
| Shares Out | 26.54M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 264,366 |
| Open | 4.91 |
| Previous Close | 4.89 |
| Day's Range | 4.81 - 5.04 |
| 52-Week Range | 4.37 - 11.30 |
| Beta | 0.77 |
| Analysts | Buy |
| Price Target | 11.17 (+122.07%) |
| Earnings Date | May 11, 2026 |
About CVRX
CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system. It sells its... [Read more]
Financial Performance
In 2025, CVRx, Inc.'s revenue was $56.65 million, an increase of 10.45% compared to the previous year's $51.29 million. Losses were -$53.31 million, -11.10% less than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for CVRX stock is "Buy." The 12-month stock price target is $11.17, which is an increase of 122.07% from the latest price.
News
CVRx, Inc. Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Leadership transition is underway with a structured CFO succession plan. Barostim therapy targets a $10B+ U.S. market, supported by strong clinical and real-world evidence. Improved reimbursement, a revamped sales force, and rising center productivity are driving 2024 growth, with a robust financial position and focus on U.S. expansion.
CVRx CFO Jared Oasheim to step down
CVRx (CVRX) announced that Jared Oasheim, the company’s CFO, will be stepping down from his role to pursue other professional opportunities. To support a transition, Oasheim will remain with the…
CVRx Announces Chief Financial Officer Transition
MINNEAPOLIS, June 09, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromo...
CVRx, Inc. Transcript: 46th Annual William Blair Growth Stock Conference
Barostim is positioned to address a large unmet need in heart failure, with strong clinical and real-world evidence supporting its efficacy and safety. Recent advances in reimbursement, including Humana's coverage, and ongoing trials could significantly expand its market and patient access.
CVRx, Inc. Slides: 46th Annual William Blair Growth Stock Conference
CVRx, Inc. has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
CVRx, Inc. Transcript: AGM 2026
The meeting confirmed quorum, elected three directors for three-year terms, and ratified the independent auditor. No questions were raised by stockholders, and forward-looking risks were highlighted in reference to the annual report.
CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
MINNEAPOLIS, May 27, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromod...
CVRx to Present at the William Blair 46th Annual Growth Stock Conference
MINNEAPOLIS, May 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromod...
CVRx announces Humana Medicare Advantage coverage policy for Barostim therapy
CVRx (CVRX) announced that Humana (HUM) has issued a Medicare Advantage coverage policy for Barostim therapy, effective May 1. Humana provides coverage to approximately 5.2M Medicare Advantage members...
CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy
MINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromod...
CVRx, Inc. Earnings Call Transcript: Q1 2026
Q1 2026 saw 20% revenue growth, improved gross margin, and narrowed net loss, with U.S. sales and reimbursement gains driving results. The launch of the BENEFIT-HF trial and transition to Category I CPT codes are expected to expand market opportunity and support long-term growth.
CVRx, Inc. Earnings release: Q1 2026
CVRx, Inc. released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
CVRx, Inc. Quarterly report: Q1 2026
CVRx, Inc. has published its Q1 2026 quarterly earnings report on May 11, 2026.
CVRx Reports First Quarter 2026 Financial and Operating Results
MINNEAPOLIS, May 11, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromod...
CVRx enrolls first patient in BENEFIT-HF trial
CVRx (CVRX) announced the enrollment of the first patient in the BENEFIT-HF trial at North Central Heart – a division of the Avera Heart Hospital, in Sioux Falls. The BENEFIT-HF…
CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population
MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for pati...
CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026
MINNEAPOLIS, April 27, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neurom...
CVRx Announces Nomination of Michael Dale for Election to the Board of Directors
MINNEAPOLIS, April 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for pa...
CVRx, Inc. Proxy statement: Proxy filing
CVRx, Inc. filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
CVRx, Inc. Proxy statement: Proxy filing
CVRx, Inc. filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
CVRx, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, April 09, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises CVRx , Inc , (“ CVRx " or the "Company") ( NASDAQ : CVRX) investors that the firm has initiated an investigation into poss...
CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting
MINNEAPOLIS, March 02, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for pa...
CVRx price target lowered to $6 from $7 at JPMorgan
JPMorgan analyst Robbie Marcus lowered the firm’s price target on CVRx (CVRX) to $6 from $7 and keeps an Underweight rating on the shares. The firm updated the company’s model…
CVRx price target lowered to $10 from $11 at Canaccord
Canaccord analyst William Plovanic lowered the firm’s price target on CVRx (CVRX) to $10 from $11 and keeps a Buy rating on the shares. The firm said they reported results…
CVRx, Inc. Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 saw revenue growth and margin improvement, driven by sales force expansion and foundational investments. The transition to Category I CPT codes and the launch of the BENEFIT-HF trial are expected to accelerate growth and expand the addressable market in 2026 and beyond.